



GLAND PHARMA LIMITED

March 03, 2026

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Change(s) in Key Management Personnel

In compliance with the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; we would like to inform you that Mr. Shyamakant Giri, Chief Executive Officer of the Company, vide his letter dated 24th February, 2026 had resigned from the services of the Company. Upon the recommendation of the Nomination and Remuneration Committee, the Board of Directors had accepted the said resignation today.

Accordingly, Mr. Shyamakant Giri ceases to be the Chief Executive Officer and Key Management Personnel of the Company from close of business hours from April 30, 2026.

The Board of Directors of the Company and the entire Gland Pharma family places on record their sincere appreciation for the leadership and contribution of Mr. Shyamakant Giri as the CEO of the Company.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the resignation letter of Mr. Shyamakant Giri, dated February 24, 2026, are enclosed herewith as Annexure A and Annexure B respectively.

This is for your information and records.

**Yours truly,
For Gland Pharma Limited**

**Sampath Kumar Pallerlamudi
Company Secretary and Compliance Officer**

Encl: Annexure A & B

**Annexure A**

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024

Details of Mr. Shyamakant Giri

SI. No	Particulars	Remarks
1	Reason for change	Resignation of Mr. Shyamakant Giri as the Chief Executive Officer and Key Managerial Personnel of the Company.
2	Date of Change	30.04.2026
3	Brief profile	Not Applicable
4	Disclosure of relationships between director	Not Applicable
5	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/24, both dated June 20, 2018	Not Applicable

24th February 2026

To,
The Executive Chairman,
Gland Pharma Limited.

Dear Mr Sadu ,

I am writing to formally resign from my position as CEO of Gland Pharma Limited .

This decision has not come easily, but after careful consideration, I believe it is the right time for me to pursue new opportunities. I want to express my sincere gratitude for the support and guidance I have received during my tenure with the company. My experiences here have been invaluable, and I am grateful for the trust you placed in me and the opportunities to learn and grow alongside a talented team.

I am committed to ensuring a smooth transition and will do everything possible to hand over my responsibilities effectively.

Thank you once again for everything.



Shyamakant Giri